Efficacy of tocilizumab treatment in severely ill COVID-19 patients.

Zhao, Jie; Cui, Wei; Tian, Bao-Ping

Zhao, Jie; Cui, Wei; Tian, Bao-Ping.

Zhao J; Department of Critical Care Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Rd., Hangzhou, 310009, Zhejiang, China.
Cui W; Department of Critical Care Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Rd., Hangzhou, 310009, Zhejiang, China.
Tian BP; Department of Critical Care Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Rd., Hangzhou, 310009, Zhejiang, China. TianBP@zju.edu.cn.

Crit Care ; 24(1): 524, 2020 08 27.

Article in English | MEDLINE | ID: covidwho-733036

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Coronavirus Infections/drug therapy; Humans; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; COVID-19 Drug Treatment

Keywords

COVID-19; Efficacy; Meta-analysis; Tocilizumab

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized Type of study: Prognostic study / Randomized controlled trials / Reviews Limits: Humans Language: English Journal: Crit Care Year: 2020 Document Type: Article Affiliation country: S13054-020-03224-7

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google